Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin

In myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows good overall response rates in heavily pretreated patients but progression-free survival data are poor. As the drug induces apo...

Descripción completa

Detalles Bibliográficos
Autores principales: Springer, Carsten, Krauter, Jürgen, Trummer, Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691812/
https://www.ncbi.nlm.nih.gov/pubmed/38039414
http://dx.doi.org/10.18632/oncotarget.28538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691812/
https://www.ncbi.nlm.nih.gov/pubmed/38039414
http://dx.doi.org/10.18632/oncotarget.28538

Ejemplares similares